Lixisenatide (Adlyxin) for Type 2 Diabetes — Weight & Metabolism
Short-acting once-daily GLP-1 receptor agonist with excellent postprandial glucose control, also available in combination with insulin glargine.
Overview
Lixisenatide is a short-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes as Adlyxin (2016). Its shorter duration of action provides particularly strong postprandial glucose-lowering effects via gastric emptying delay. The ELIXA cardiovascular outcomes trial (n=6,068, median 2.1 years, post-ACS population) confirmed cardiovascular safety (HR 1.02, 95% CI 0.89-1.17) without excess risk. HbA1c reductions of 0.7-1.0% across GetGoal clinical trials. Available as Soliqua 100/33 (lixisenatide 33mcg + insulin glargine 100 units/mL) for complementary basal-bolus coverage. Weight neutral to modest weight loss (~1-2 kg). PMID: 26254598, 27633186, 23727171.
Indications
- Type 2 diabetes mellitus as adjunct to diet and exercise
- Add-on to basal insulin for improved postprandial glucose control (Soliqua)
- Patients with predominant postprandial hyperglycemia requiring targeted glucose excursion control
Mechanism of Action
Impaired first-phase insulin response and rapid gastric emptying lead to excessive post-meal glucose spikes
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Lixisenatide | 10 mcg | Once daily (within 1 hour before first meal) | Starting dose for 14 days to establish GI tolerance |
| Lixisenatide | 20 mcg | Once daily (within 1 hour before first meal) | Target maintenance dose from day 15 onward; fixed dose, no further titration |
| Lixisenatide + Insulin Glargine | 15-60 units glargine / 5-20 mcg lixisenatide | Once daily (within 1 hour before first meal) | Fixed-ratio combination pen; titrate based on fasting glucose (target 80-130 mg/dL) |
Evidence Grade
GRADE A
Safety & Contraindications
- FDA-approved since 2016 with cardiovascular safety confirmed in ELIXA trial
- Black box warning: thyroid C-cell tumors in rodents; contraindicated with MTC/MEN2 history
- Common GI side effects: nausea (25%), vomiting (10%), diarrhea (8%) - most common during first 2-3 weeks
- Risk of hypoglycemia when combined with sulfonylureas or basal insulin - adjust concomitant medications
- May slow absorption of oral medications due to gastric emptying delay; take oral meds 1 hour before lixisenatide
- Not studied in patients with gastroparesis; use with caution in severe GI disease